Novel Eye Drop to Relieve Presbyopia Enters Phase 3 Clinicals

By
Orasis Pharmaceuticals, an Israeli-based ophthalmic pharmaceutical company announced the start of Phase 3 clinical studies in the U.S. to evaluate novel eye drop candidate, CSF-1, designed to provide temporary correction of presbyopia. Read More